Advisory Alpha, LLC Editas Medicine, Inc. Transaction History

Advisory Alpha, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$27.07 - $84.35 $2,707 - $8,435	-100 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$28.06 - $37.16 $2,806 - $3,715	100 New	100 $3,000
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $1,850 - $3,434	-100 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$22.49 - $26.81 $2,249 - $2,681	100 New	100 $2,000
Q2 2019 Aug 16, 2019	SELL	$20.48 - $27.76 $2,048 - $2,776	-100 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$19.43 - $26.41 $1,943 - $2,641	100 New	100 $0

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Advisory Alpha, LLC, based on Form 13F filings with the SEC.

Stay updated on Advisory Alpha, LLC with notifications on news.